Invivyd, Inc. (IVVD)Healthcare | Biotechnology | New Haven, United States | NasdaqGM
0.96 USD
+0.06
(7.155%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.96 0.00 (-0.002%) ⇩ (Aug. 28, 2026, 7:44 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:52 a.m. EDT
The investment case here is fundamentally broken. The company has endured four consecutive years of double-digit percentage declines, erasing nearly 98% of its value since the 2021 peak. While the balance sheet currently appears liquid with minimal debt, the business is hemorrhaging cash with negative operating and free cash flows, and it is burning through its treasury reserves without generating revenue growth. The recent price action shows a fragile recovery attempt, but the statistical forecast model offers no directional guidance, reflecting the extreme noise and lack of predictable momentum in such a distressed biotech stock. With no dividend to provide income and a trajectory that suggests the market has permanently downgraded the asset's quality, this remains a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.167589 |
| MSTL | 0.220126 |
| AutoARIMA | 0.223549 |
| AutoETS | 0.223549 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 82.53 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.046 |
| Excess Kurtosis | -0.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.634 |
| Revenue per Share | 0.216 |
| Market Cap | 284,294,816 |
| Forward P/E | -1.75 |
| Beta | 0.71 |
| Profit Margins | -183.90% |
| Previous Name | Adagio Therapeutics, Inc. |
| Website | https://www.invivyd.com |
As of Aug. 22, 2026, 5:52 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes at $0.50 and $2.00) compared to negligible call volume. The call side shows a 'top of the mountain' concentration at the $1.50 strike, suggesting a speculative bet on a bounce to that level, but the overwhelming put weight indicates the market views the current price as vulnerable to further declines.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.063106775 |
| Address1 | 209 Church Street |
| All Time High | 78.82 |
| All Time Low | 0.355 |
| Ask | 0.754 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 4,663,060 |
| Average Daily Volume3 Month | 4,599,076 |
| Average Volume | 4,599,076 |
| Average Volume10Days | 4,663,060 |
| Beta | 0.708 |
| Bid | 0.4092 |
| Bid Size | 2 |
| Book Value | 0.614 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.9645 |
| Current Ratio | 5.869 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.97 |
| Day Low | 0.894 |
| Debt To Equity | 4.634 |
| Display Name | Invivyd |
| Earnings Call Timestamp End | 1,778,761,800 |
| Earnings Call Timestamp Start | 1,778,761,800 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -111,888,000 |
| Ebitda Margins | -1.91704 |
| Enterprise To Ebitda | -1.185 |
| Enterprise To Revenue | 2.272 |
| Enterprise Value | 132,605,808 |
| Eps Current Year | -0.57 |
| Eps Forward | -0.55 |
| Eps Trailing Twelve Months | -0.33 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.78164 |
| Fifty Day Average Change | 0.18286002 |
| Fifty Day Average Change Percent | 0.23394404 |
| Fifty Two Week Change Percent | -6.3106775 |
| Fifty Two Week High | 3.07 |
| Fifty Two Week High Change | -2.1055 |
| Fifty Two Week High Change Percent | -0.68583065 |
| Fifty Two Week Low | 0.528 |
| Fifty Two Week Low Change | 0.4365 |
| Fifty Two Week Low Change Percent | 0.82670456 |
| Fifty Two Week Range | 0.528 - 3.07 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,628,256,600,000 |
| Float Shares | 207,831,444 |
| Forward Eps | -0.55 |
| Forward P E | -1.7536364 |
| Free Cashflow | -69,950,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 122 |
| Fullday Change | 0.0644 |
| Fullday Change Percent | 7.15476 |
| Fullday Price | 0.9626 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.92233 |
| Gross Profits | 53,832,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07163 |
| Held Percent Institutions | 0.86408997 |
| Implied Shares Outstanding | 294,758,746 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut. |
| Long Name | Invivyd, Inc. |
| Market | us_market |
| Market Cap | 284,294,816 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_677282690 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -107,333,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 265,312,347 |
| Number Of Analyst Opinions | 3 |
| Open | 0.9062 |
| Operating Cashflow | -108,422,000 |
| Operating Margins | -3.20756 |
| Payout Ratio | 0.0 |
| Phone | 781 819 0080 |
| Post Market Change | -0.0019000173 |
| Post Market Change Percent | -0.19699505 |
| Post Market Price | 0.9626 |
| Post Market Time | 1,787,960,696 |
| Prev Name | Adagio Therapeutics, Inc. |
| Previous Close | 0.9001 |
| Price Eps Current Year | -1.6921053 |
| Price Hint | 4 |
| Price To Book | 1.5708469 |
| Price To Sales Trailing12 Months | 4.870981 |
| Profit Margins | -1.839 |
| Quick Ratio | 5.536 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.0644 |
| Regular Market Change Percent | 7.15476 |
| Regular Market Day High | 0.97 |
| Regular Market Day Low | 0.894 |
| Regular Market Day Range | 0.894 - 0.97 |
| Regular Market Open | 0.9062 |
| Regular Market Previous Close | 0.9001 |
| Regular Market Price | 0.9645 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 3,575,681 |
| Return On Assets | -0.45668 |
| Return On Equity | -0.95889 |
| Revenue Growth | 0.212 |
| Revenue Per Share | 0.216 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 294,758,746 |
| Shares Percent Shares Out | 0.104899995 |
| Shares Short | 30,916,751 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 29,311,996 |
| Short Name | Invivyd, Inc. |
| Short Percent Of Float | 0.1159 |
| Short Ratio | 10.66 |
| Source Interval | 15 |
| State | CT |
| Symbol | IVVD |
| Target High Price | 10.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 160,080,000 |
| Total Cash Per Share | 0.543 |
| Total Debt | 8,391,000 |
| Total Revenue | 58,365,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.33 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.52394 |
| Two Hundred Day Average Change | -0.55943996 |
| Two Hundred Day Average Change Percent | -0.36710104 |
| Type Disp | Equity |
| Volume | 3,575,681 |
| Website | https://www.invivyd.com |
| Zip | 6,510 |